{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:19Z","timestamp":1787721679468,"version":"build-2784847793"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Selective serotonin reuptake inhibitors (SSRIs) are recognized for their antidepressant effects and their potential role in promoting neuroplasticity. This systematic review and meta-analysis aimed to evaluate whether SSRIs improve prognostic outcomes in patients with stroke compared with placebo or no intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the Cochrane Library, PubMed, and Embase databases to identify randomized controlled trials comparing SSRIs with placebo or no intervention in patients with stroke. Continuous outcomes were pooled using weighted mean differences (WMDs), and dichotomous outcomes were pooled using risk ratios (RRs), both with 95% confidence intervals (CIs). Fixed-effect or random-effects models were selected according to the degree of statistical heterogeneity for each outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven reports from nine unique randomized controlled trials, involving 7,604 unique participants, were included. In exploratory analyses stratified by follow-up duration, SSRI use at 3\u202fmonths was associated with better modified Rankin Scale (mRS) responder status and a greater absolute reduction in National Institutes of Health Stroke Scale score (absNIHSS) (RR 2.46, 95% CI 1.74\u20133.48; WMD 0.57, 95% CI 0.11\u20131.03). However, the 3-month mRS finding was derived from a single trial and should therefore be interpreted with particular caution. At 6\u202fmonths, SSRI use was associated with a smaller absolute reduction in NIHSS score (WMD \u22120.23, 95% CI\u20130.45 to \u22120.02), but this finding should also be interpreted cautiously because the absNIHSS analysis showed substantial heterogeneity. At 12\u202fmonths, SSRI use was associated with a lower risk of recurrent stroke (RR 0.65, 95% CI 0.47\u20130.89), particularly recurrent ischemic stroke (RR 0.57, 95% CI 0.40\u20130.80). These findings suggest that the observed associations between SSRI use and stroke outcomes varied across follow-up-duration subgroups. However, these subgroup patterns should be interpreted cautiously because they may reflect differences in study populations, follow-up designs, attrition, rehabilitation strategies, and trial weighting rather than a confirmed biological time-dependent effect. No statistically significant differences were observed in thrombotic events, bleeding events, mortality, cardiac adverse events, or drug-specific subgroup analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SSRI use after stroke may be associated with selected exploratory short-term functional signals and a lower long-term risk of recurrent stroke, particularly recurrent ischemic stroke. However, the apparent short-term mRS benefit was driven by a single trial and should not be interpreted as a robust or generalizable clinical effect. The mid-term absNIHSS findings did not support a sustained functional benefit and were accompanied by substantial heterogeneity. Therefore, the functional outcome findings should be interpreted as exploratory rather than definitive. The observed associations should be interpreted cautiously because they were derived from exploratory follow-up-duration-stratified analyses and represent subgroup-level associations rather than evidence of a causal temporal or biological effect of SSRIs. Further well-designed randomized controlled trials are needed to clarify the optimal timing, duration, and safety of SSRI therapy after stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1894976","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:24Z","timestamp":1787719944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The influence of selective serotonin reuptake inhibitors on stroke outcome: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuanhui","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pediatric, The First Affiliation Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/17474930211065917","article-title":"World stroke organization (WSO): global stroke fact sheet 2022","volume":"17","author":"Feigin","year":"2022","journal-title":"Int J Stroke"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/STR.0000000000000098","article-title":"Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"47","author":"Winstein","year":"2016","journal-title":"Stroke"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0140-6736(20)31179-x","article-title":"Stroke","volume":"396","author":"Campbell","year":"2020","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2017.5706","article-title":"Management of depression in older adults: a review","volume":"317","author":"Kok","year":"2017","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(10)70314-8","article-title":"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial","volume":"10","author":"Chollet","year":"2011","journal-title":"The Lancet Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e00373","DOI":"10.1002\/brb3.373","article-title":"Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence","volume":"5","author":"Siepmann","year":"2015","journal-title":"Brain Behav"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/00004647-199912000-00010","article-title":"Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks","volume":"19","author":"Loubinoux","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/jnr.21899","article-title":"Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect","volume":"87","author":"Lim","year":"2009","journal-title":"J Neurosci Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"CD009286","DOI":"10.1002\/14651858.CD009286.pub4","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery","volume":"2021","author":"Legg","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"CD009286","DOI":"10.1002\/14651858.CD009286.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery","volume":"2019","author":"Legg","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8930","DOI":"10.1590\/1414-431X20208930","article-title":"Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction","volume":"53","author":"Cao","year":"2020","journal-title":"Braz J Med Biol Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"734170","DOI":"10.3389\/fneur.2021.734170","article-title":"Sertraline for functional recovery after acute ischemic stroke: a prospective observational study","volume":"12","author":"Stuckart","year":"2021","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40268-019-00287-y","article-title":"Use of selective serotonin reuptake inhibitors and outcomes in stroke rehabilitation: a prospective observational pilot cohort study","volume":"19","author":"Yeo","year":"2019","journal-title":"Drugs R D"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1161\/STROKEAHA.120.033070","article-title":"Twelve-month outcomes of the AFFINITY trial of fluoxetine for functional recovery after acute stroke: AFFINITY trial steering committee on behalf of the AFFINITY trial collaboration","volume":"52","author":"Hankey","year":"2021","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1001\/jama.299.20.2391","article-title":"Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial","volume":"299","author":"Robinson","year":"2008","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.035","article-title":"Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China","volume":"25","author":"He","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/1545968317704902","article-title":"Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial","volume":"31","author":"Savadi Oskouie","year":"2017","journal-title":"Neurorehabil Neural Repair"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2018.02.029","article-title":"Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study","volume":"168","author":"He","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1161\/STROKEAHA.117.020067","article-title":"Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS) a randomized controlled study","volume":"49","author":"Kraglund","year":"2018","journal-title":"Stroke"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0140-6736(18)32823-X","article-title":"Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.5603\/PJNNS.a2020.0099","article-title":"Fluoxetine for stroke recovery improvement\u2014the doubleblind, randomised placebo-controlled FOCUS-Poland trial","volume":"54","author":"Bembenek","year":"2020","journal-title":"Neurol Neurochir Pol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1474-4422(20)30207-6","article-title":"Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial","volume":"19","author":"Hankey","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(20)30219-2","article-title":"Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial","volume":"19","author":"Lundstr\u00f6m","year":"2020","journal-title":"The Lancet Neurology."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1161\/STROKEAHA.121.034705","article-title":"Effects of fluoxetine on outcomes at 12 months after acute stroke: results from EFFECTS, a randomized controlled trial","volume":"52","author":"Lundstr\u00f6m","year":"2021","journal-title":"Stroke"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2013.04.011","article-title":"Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice","volume":"247","author":"Espinera","year":"2013","journal-title":"Neuroscience"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00702-015-1407-3","article-title":"Direct inhibition of retinoic acid catabolism by fluoxetine","volume":"122","author":"Hellmann-Regen","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"ref28","first-page":"7","article-title":"Clinical observation of combined matrine metronidazole tablets membrane in the treatment of bacterial vaginitis in 40 cases","volume":"5","author":"Chen","year":"2014","journal-title":"J Practical Gynecologic Endocrinology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"111952","DOI":"10.1016\/j.bbr.2019.111952","article-title":"Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus","volume":"370","author":"Xu","year":"2019","journal-title":"Behav Brain Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00392-020-01697-8","article-title":"The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis","volume":"110","author":"Fernandes","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1160\/TH17-04-0288","article-title":"Escitalopram impairs thrombin-induced platelet response, cytoskeletal assembly and activation of associated signalling pathways","volume":"117","author":"Lopez-Vilchez","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1111\/j.1582-4934.2012.01596.x","article-title":"Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO\/muscarinic signalling","volume":"16","author":"Ofek","year":"2012","journal-title":"J Cell Mol Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.4088\/JCP.v65n1209","article-title":"Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review","volume":"65","author":"Ramasubbu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"121836","DOI":"10.1016\/j.jad.2026.121836","article-title":"Risk of stroke among individuals on selective serotonin reuptake inhibitors (SSRIs) versus non-SSRI antidepressants: a population-based retrospective cohort study and meta-analysis","volume":"408","author":"Sun","year":"2026","journal-title":"J Affect Disord"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1161\/STROKEAHA.120.032973","article-title":"Risk of fractures in stroke patients treated with a selective serotonin reuptake inhibitor: a systematic review and Meta-analysis","volume":"52","author":"Jones","year":"2021","journal-title":"Stroke"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1570159X17666190726104139","article-title":"Pharmacological interventions and rehabilitation approach for enhancing brain self-repair and stroke recovery","volume":"18","author":"Szelenberger","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/14656566.2021.1880566","article-title":"Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance","volume":"22","author":"Mortensen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/17448069211063351","article-title":"Tricyclic antidepressants and selective serotonin reuptake inhibitors but not anticonvulsants ameliorate pain, anxiety, and depression symptoms in an animal model of central post-stroke pain","volume":"17","author":"Shyu","year":"2021","journal-title":"Mol Pain"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3389\/fnins.2017.00637","article-title":"SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus","volume":"11","author":"Pinto","year":"2017","journal-title":"Front Neurosci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1894976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:37Z","timestamp":1787719957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1894976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":39,"alternative-id":["10.3389\/fneur.2026.1894976"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1894976","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1894976"}}